#Switzerland #Drug Pricing #EVERSANA #Basel #Lyfegen

Introduction

In a groundbreaking move, Lyfegen, a pioneer in drug market access and pricing innovation, has announced a strategic collaboration with EVERSANA, a leading provider in global commercial services for the life sciences sector. This partnership aims to integrate advanced artificial intelligence insights into drug pricing and market access. The goal? To tackle the rising costs of pharmaceuticals and enhance patient accessibility worldwide.

Collaboration Overview

Set against the backdrop of soaring drug prices, this collaboration combines the strengths of two formidable platforms: EVERSANA's NAVLIN and Lyfegen's Public Drug Agreement Library.

• - NAVLIN by EVERSANA: This platform provides real-time global pricing and access data across over 100 countries and more than 50 health technology assessment (HTA) bodies. It offers essential insights into current market dynamics.

• - Lyfegen’s Public Drug Agreement Library: With a repository containing over 7,000 public pricing agreements, this library equips market access professionals with real-world informed strategies, enabling better decision-making.

Together, these systems present a powerful toolkit that enables market access teams to gain comprehensive insights into pricing trends and access frameworks, all enhanced by AI capabilities.

Simplifying Complexity with AI

The complexity surrounding drug pricing has become more pronounced, leading to inefficiencies and delays for healthcare payers and pharmaceutical companies. The Lyfegen and EVERSANA collaboration aims to streamline this process.

• - Integration Benefits: By integrating these two vital resources, users can efficiently manage pricing agreements and access data within a unified platform. This integration aids in discovering tailored agreements for specific market needs while utilizing predictive analytics to streamline decision-making processes.

• - Adaptive to Market Changes: As regulations and market trends shift, the tools provided through this collaboration allow users to adapt quickly, minimizing delays in bringing therapies to patients.

The partnership fundamentally rethinks how market access decisions are made—emphasizing speed, efficiency, and fairness.

Driving Smarter Decisions

This collaboration will significantly empower market access teams to make informed and equitable decisions. By harnessing AI-driven insights, pharmaceutical companies and payers can tackle inefficiencies that compromise patient access to crucial therapies.

Jim Lang, CEO of EVERSANA, expressed excitement regarding this collaboration: "Together with Lyfegen, we can harness the power of AI to address one of the biggest challenges in healthcare—helping patients get timely access to life-saving medicines." This statement underscores the partnership's potential impact on the healthcare landscape.

Vision for the Future

As the healthcare industry evolves rapidly, the integration of AI technology becomes increasingly essential. This partnership positions Lyfegen and EVERSANA as leaders in this transformative wave, allowing stakeholders to navigate the complexity of drug affordability more effectively.

Girisha Fernando, CEO of Lyfegen, highlighted the partnership's mission: "Through this partnership with EVERSANA, we are taking a giant step toward creating a more sustainable and equitable healthcare environment." This collaboration represents a significant leap toward a better future for drug pricing and accessibility.

About Lyfegen and EVERSANA

Lyfegen, established in 2018 and headquartered in Basel, Switzerland, serves as an independent provider of rebate management software tailored for the healthcare industry. The company houses the world's most extensive repository of drug access agreements and integrates powerful pricing simulation tools to support payers in optimizing their processes.

EVERSANA is a prominent independent service provider for the life sciences sector, whose comprehensive solutions are designed around patient experiences and span all stages of the product lifecycle, ensuring value for all healthcare stakeholders.

Conclusion

The collaboration between Lyfegen and EVERSANA is more than just a partnership; it signifies a foundational shift toward more intelligent, responsive, and equitable drug pricing strategies. By exploring AI as a tool for enhancing access to vital medications, both companies are on the cutting edge of transforming patient care on a global scale.